Adnectin–drug conjugates for Glypican-3-specific delivery of a cytotoxic payload to tumors

Tumor-specific delivery of cytotoxic agents remains a challenge in cancer therapy. Antibody–drug conjugates (ADC) deliver their payloads to tumor cells that overexpress specific tumor-associated antigens—but the multi-day half-life of ADC leads to high exposure even of normal, antigen-free, tissues...

Descripción completa

Detalles Bibliográficos
Autores principales: Lipovšek, Daša, Carvajal, Irvith, Allentoff, Alban J, Barros, Anthony, Brailsford, John, Cong, Qiang, Cotter, Pete, Gangwar, Sanjeev, Hollander, Cris, Lafont, Virginie, Lau, Wai Leung, Li, Wenying, Moreta, Miguel, O’Neil, Steven, Pinckney, Jason, Smith, Michael J, Su, Julie, Terragni, Christina, Wallace, Michael A, Wang, Lifei, Wright, Martin, Marsh, H Nicholas, Bryson, James W
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6158766/
https://www.ncbi.nlm.nih.gov/pubmed/30247737
http://dx.doi.org/10.1093/protein/gzy013

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6158766/
https://www.ncbi.nlm.nih.gov/pubmed/30247737
http://dx.doi.org/10.1093/protein/gzy013

Ejemplares similares